


Disappearance of Antibodies to SARS-Associated Coronavirus after Recovery

TO THE EDITOR: Previous studies have demonstrated that IgG and neutralizing antibodies against coronavirus associated with the severe acute respiratory syndrome (SARS) may persist, in spite of a decline in titer, for 2 years in patients who have recovered from SARS.^{1,2} For 3 years, we followed



patients who had recovered from infection with SARS-associated coronavirus, to measure the longevity of specific antibodies.

Fifty-six patients who were positive for serum IgG and neutralizing antibodies against SARS-associated coronavirus at the time of recovery from acute SARS infection were included in this study.¹ The titers of IgG and neutralizing antibodies were significantly correlated during the 3-year follow-up period (Spearman's correlation coefficient, 0.905; $P=0.002$). The titers peaked at month 4 and diminished thereafter (Fig. 1). IgG and neutralizing antibodies were undetectable in 19.4% and 11.1% of serum samples, respectively, at month 30, and in 25.8% and 16.1%, respectively, at month 36. For the IgG antibody, the geometric mean reciprocal titers dropped from 244 at month 4 to 34 at month 30 and 28 at month 36. For the neutralizing antibody, the geometric mean reciprocal titers dropped from 1232 at month 4 to 32 at month 30 and remained at that value through month 36. There were no significant differences in the kinetics of specific antibodies according to disease severity, duration of hospitalization, type and number of coexisting conditions, or use or nonuse of corticosteroids. However, the 19 patients with subsequent aseptic femoral neck necrosis had significantly lower neutralizing antibody levels than the 37 without the sequela ($P<0.001$, from mixed-linear random-effects models).

Experiments in animals indicate that IgG and neutralizing antibodies, along with T-cell mediated immunity, are essential for protection against live-virus challenge.^{3,4} Our data suggest that immune protection may wane over time, as demonstrated in patients infected with human coronavirus 229E.⁵ How this waning humoral immunity may affect future SARS-associated disease in the

context of reexposure to SARS is unknown. In the absence of another SARS outbreak, we do not know whether lower or even undetectable levels of specific antibodies would be adequate to protect a person from reinfection due to a potential anamnestic response, as seen with other viral infections such as measles and hepatitis A. The implications of the lower neutralizing antibody levels in patients with aseptic femoral neck necrosis are unclear.

Wu-Chun Cao, M.D., Ph.D.

Wei Liu, M.D., Ph.D.

State Key Laboratory of Pathogen and Biosecurity
Beijing 100071, China
caowc@nic.bmi.ac.cn

Pan-He Zhang, M.Sc.

Fang Zhang, M.D.

Beijing Institute of Microbiology and Epidemiology
Beijing 100071, China

Jan H. Richardus, M.D., Ph.D.

Erasmus Medical Center
3015 GE Rotterdam, the Netherlands

Supported by grants from the Commission of the European Community and the National 863 High-Tech Program of China.

No potential conflict of interest relevant to this letter was reported.

1. Liu W, Fontanet A, Zhang PH, et al. Two-year prospective study of the humoral immune response of patients with severe acute respiratory syndrome. *J Infect Dis* 2006;193:792-5.
2. Mo H, Zeng G, Ren X, et al. Longitudinal profile of antibodies against SARS-coronavirus in SARS patients and their clinical significance. *Respirology* 2006;11:49-53.
3. Yang ZY, Kong WP, Huang Y, et al. A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. *Nature* 2004;428:561-4.
4. Subbarao K, McAuliffe J, Vogel L, et al. Prior infection and passive transfer of neutralizing antibody prevent replication of severe acute respiratory syndrome coronavirus in the respiratory tract of mice. *J Virol* 2004;78:3572-7.
5. Callow KA, Parry HF, Sergeant M, Tyrrell DA. The time course of the immune response to experimental coronavirus infection of man. *Epidemiol Infect* 1990;105:435-46.

Correspondence Copyright © 2007 Massachusetts Medical Society.

INSTRUCTIONS FOR LETTERS TO THE EDITOR

Letters to the Editor are considered for publication, subject to editing and abridgment, provided they do not contain material that has been submitted or published elsewhere. Please note the following: •Letters in reference to a *Journal* article must not exceed 175 words (excluding references) and must be received within 3 weeks after publication of the article. Letters not related to a *Journal* article must not exceed 400 words. All letters must be submitted over the Internet at <http://authors.nejm.org>. •A letter can have no more than five references and one figure or table. •A letter can be signed by no more than three authors. •Financial associations or other possible conflicts of interest must be disclosed. (Such disclosures will be published with the letters. For authors of *Journal* articles who are responding to letters, this information appears in the published articles.) •Include your full mailing address, telephone number, fax number, and e-mail address with your letter.

Our Web site: <http://authors.nejm.org>

We cannot acknowledge receipt of your letter, but we will notify you when we have made a decision about publication. Letters that do not adhere to these instructions will not be considered. Rejected letters and figures will not be returned. We are unable to provide prepublication proofs. Submission of a letter constitutes permission for the Massachusetts Medical Society, its licensees, and its assignees to use it in the *Journal's* various print and electronic publications and in collections, revisions, and any other form or medium.